Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, investigator-blind, comparative Phase 3 study. Patients will receive
either iclaprim or linezolid for 10 to 14 days. Patients will be evaluated daily for the
first four days of study treatment and then every other day, for up to 14 days of the
treatment period, at End of Therapy, the Test Of Cure visit (7 to 14 days post treatment),
and a Late Follow-up (F/U) visit (7 to 14 days after the TOC visit).